Details:
The Prospective Study of Pegloticase in Transplant patients trial is an ongoing Phase 4, open-label trial evaluating the safety and efficacy of KRYSTEXXA in adults with uncontrolled gout who have received a kidney transplant and are on stable immunosuppressive therapy.
Lead Product(s): Pegloticase
Therapeutic Area: Musculoskeletal Product Name: Krystexxa
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
PROTECT trial evaluating the use of KRYSTEXXA (pegloticase injection) in people with chronic gout refractory to conventional therapies who have received a kidney transplant, as well as pharmacokinetic data regarding the concomitant use of KRYSTEXXA and methotrexate.
Lead Product(s): Pegloticase
Therapeutic Area: Musculoskeletal Product Name: Krystexxa
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.
Lead Product(s): Neostigmine Methylsulfate
Therapeutic Area: Musculoskeletal Product Name: Bloxiverz
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Exela Pharma Sciences, LLC.
Deal Size: $42.0 million Upfront Cash: $14.5 million
Deal Type: Divestment July 01, 2020